A Phase I-II Study of Systemic Capecitabine, Cisplatin and Intraperitoneal Docetaxel (XPID) in Patients With Advanced Stomach Cancer With Peritoneal Seeding
Single-center, open-label, prospective, single-arm, phase I-II study
About 37 patients (Phase I 18, Phase II 31 (including 12 patients from Phase I)
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Maximum tolerated dose
Phase I Study - Maximum tolerated dose of Intraperitoneal Docetaxel Phase II Study Progression-free survival rate at 6 months response rate, time to progression, overall survival
1 year
No
Min-Hee Ryu, MD
Principal Investigator
Asan Medical Center/Univ of Ulsan
South Korea: Institutional Review Board
AMC-XPID-1
NCT01525771
February 2011
December 2014
Name | Location |
---|